Alastair J Florence

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7040345/publications.pdf

Version: 2024-02-01

152 papers	4,312 citations	81900 39 h-index	128289 60 g-index
157 all docs	157 docs citations	157 times ranked	3975 citing authors

#	Article	IF	Citations
1	Effect of oscillatory flow conditions on crystalliser fouling investigated through non-invasive imaging. Chemical Engineering Science, 2022, 252, 117188.	3.8	9
2	Precrystallization solute assemblies and crystal symmetry. Faraday Discussions, 2022, 235, 307-321.	3.2	2
3	Direct Image Feature Extraction and Multivariate Analysis for Crystallization Process Characterization. Crystal Growth and Design, 2022, 22, 2105-2116.	3.0	3
4	Crystal Structure and Twisted Aggregates of Oxcarbazepine Form III. Crystal Growth and Design, 2022, 22, 4146-4156.	3.0	2
5	Mechanistic insights of evaporation-induced actuation in supramolecular crystals. Nature Materials, 2021, 20, 403-409.	27.5	44
6	The Ambiguous Functions of the Precursors That Enable Nonclassical Modes of Olanzapine Nucleation and Growth. Crystals, 2021, 11, 738.	2.2	3
7	Heat Transfer and Residence Time Distribution in Plug Flow Continuous Oscillatory Baffled Crystallizers. ACS Omega, 2021, 6, 18352-18363.	3.5	8
8	Investigation of Wet Milling and Indirect Ultrasound as Means for Controlling Nucleation in the Continuous Crystallization of an Active Pharmaceutical Ingredient. Organic Process Research and Development, 2021, 25, 2119-2132.	2.7	8
9	Olanzapine crystal symmetry originates in preformed centrosymmetric solute dimers. Nature Chemistry, 2020, 12, 914-920.	13.6	26
10	Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies. Molecular Pharmaceutics, 2020, 17, 2232-2244.	4.6	41
11	Development and characterisation of a cascade of moving baffle oscillatory crystallisers (CMBOC). CrystEngComm, 2020, 22, 2288-2296.	2.6	5
12	Reversible, Two-Step Single-Crystal to Single-Crystal Phase Transitions between Desloratadine Forms I, II, and III. Crystal Growth and Design, 2020, 20, 1800-1810.	3.0	20
13	A micro-XRT image analysis and machine learning methodology for the characterisation of multi-particulate capsule formulations. International Journal of Pharmaceutics: X, 2020, 2, 100041.	1.6	7
14	Manual Versus Microfluidic-Assisted Nanoparticle Manufacture: Impact of Silk Fibroin Stock on Nanoparticle Characteristics. ACS Biomaterials Science and Engineering, 2020, 6, 2796-2804.	5.2	28
15	Peptide Isolation via Spray Drying: Particle Formation, Process Design and Implementation for the Production of Spray Dried Glucagon. Pharmaceutical Research, 2020, 37, 255.	3.5	6
16	Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisolâ„¢ 15LV filaments for fused filament fabrication (FFF) 3D printing. Additive Manufacturing, 2019, 29, 100776.	3.0	36
17	Use of Terahertz-Raman Spectroscopy to Determine Solubility of the Crystalline Active Pharmaceutical Ingredient in Polymeric Matrices during Hot Melt Extrusion. Molecular Pharmaceutics, 2019, 16, 4361-4371.	4.6	17
18	Why We Need Continuous Pharmaceutical Manufacturing and How to Make It Happen. Journal of Pharmaceutical Sciences, 2019, 108, 3521-3523.	3.3	75

#	Article	IF	Citations
19	Engineering of acetaminophen particle attributes using a wet milling crystallisation platform. International Journal of Pharmaceutics, 2019, 554, 201-211.	5.2	26
20	Enabling precision manufacturing of active pharmaceutical ingredients: workflow for seeded cooling continuous crystallisations. Molecular Systems Design and Engineering, 2018, 3, 518-549.	3.4	66
21	A random forest model for predicting crystal packing of olanzapine solvates. CrystEngComm, 2018, 20, 3947-3950.	2.6	13
22	Impact of Paracetamol Impurities on Face Properties: Investigating the Surface of Single Crystals Using TOF-SIMS. Crystal Growth and Design, 2018, 18, 2750-2758.	3.0	10
23	Rapid Continuous Antisolvent Crystallization of Multicomponent Systems. Crystal Growth and Design, 2018, 18, 210-218.	3.0	16
24	Multi-sensor inline measurements of crystal size and shape distributions during high shear wet milling of crystal slurries. Advanced Powder Technology, 2018, 29, 2987-2995.	4.1	16
25	Quantitative investigation of particle formation of a model pharmaceutical formulation using single droplet evaporation experiments and X-ray tomography. Advanced Powder Technology, 2018, 29, 2996-3006.	4.1	15
26	Successful Computationally Directed Templating of Metastable Pharmaceutical Polymorphs. Crystal Growth and Design, 2018, 18, 5322-5331.	3.0	52
27	Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing. Annual Review of Chemical and Biomolecular Engineering, 2018, 9, 253-281.	6.8	104
28	Spray Drying as a Reliable Route to Produce Metastable Carbamazepine Form IV. Journal of Pharmaceutical Sciences, 2017, 106, 1874-1880.	3.3	21
29	Aqueous Solubility of Organic Salts. Investigating Trends in a Systematic Series of 51 Crystalline Salt Forms of Methylephedrine. Crystal Growth and Design, 2017, 17, 3277-3286.	3.0	17
30	Relating induction time and metastable zone width. CrystEngComm, 2017, 19, 3966-3978.	2.6	36
31	Mesoscopic Solute-Rich Clusters in Olanzapine Solutions. Crystal Growth and Design, 2017, 17, 6668-6676.	3.0	26
32	Direct Observation of Templated Two-Step Nucleation Mechanism during Olanzapine Hydrate Formation. Crystal Growth and Design, 2017, 17, 6382-6393.	3.0	41
33	Combined Chemoinformatics Approach to Solvent Library Design Using clusterSim and Multidimensional Scaling. Journal of Chemical Information and Modeling, 2017, 57, 1807-1815.	5.4	4
34	A factorial approach to understanding the effect of inner geometry of baffled meso-scale tubes on solids suspension and axial dispersion in continuous, oscillatory liquidâ€“solid plug flows. Chemical Engineering Journal, 2017, 308, 669-682.	12.7	37
35	Template-induced targeted crystallisation of computationally predicted polymorphs. Acta Crystallographica Section A: Foundations and Advances, 2017, 73, C1414-C1414.	0.1	0
36	Isomorphous template induced crystallisation: a robust method for the targeted crystallisation of computationally predicted metastable polymorphs. Chemical Communications, 2016, 52, 7384-7386.	4.1	57

#	Article	IF	Citations
37	Crystal structure of the co-crystal butylparabenâ€“isonicotinamide (1/1). Acta Crystallographica Section E: Crystallographic Communications, 2016, 72, 53-55.	0.5	2
38	Effect of Oscillatory Flow on Nucleation Kinetics of Butyl Paraben. Crystal Growth and Design, 2016, 16, 875-886.	3.0	19
39	Oscillatory Flow Reactors (OFRs) for Continuous Manufacturing and Crystallization. Organic Process Research and Development, 2015, 19, 1186-1202.	2.7	165
40	Image-based monitoring for early detection of fouling in crystallisation processes. Chemical Engineering Science, 2015, 133, 82-90.	3.8	23
41	A random forest model for predicting the crystallisability of organic molecules. CrystEngComm, 2015, 17, 4272-4275.	2.6	19
42	Crystal structure of a mixed solvated form of amoxapine acetate. Acta Crystallographica Section E: Crystallographic Communications, 2015, 71, 139-141.	0.5	1
43	Seeded Crystallization of Î²-<scp>l</scp>-Glutamic Acid in a Continuous Oscillatory Baffled Crystallizer. Organic Process Research and Development, 2015, 19, 1903-1911.	2.7	69
44	Establishment of a Continuous Sonocrystallization Process for Lactose in an Oscillatory Baffled Crystallizer. Organic Process Research and Development, 2015, 19, 1871-1881.	2.7	67
45	Achieving Continuous Manufacturing: Technologies and Approaches for Synthesis, Workup, and Isolation of Drug Substance May 20â€“21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences, 2015, 104, 781-791.	3.3	129
46	Formulation of Liquid Propofol as a Cocrystalline Solid. Crystal Growth and Design, 2014, 14, 2422-2430.	3.0	35
47	From discovery to scale-up: Î±-lipoic acidâ€‰:â€‰nicotinamide co-crystals in a continuous oscillatory baffled crystalliser. CrystEngComm, 2014, 16, 5769-5780.	2.6	64
48	Drug solid solutions â€“ a method for tuning phase transformations. CrystEngComm, 2014, 16, 5827-5831.	2.6	29
49	Structure and stability of two polymorphs of creatine and its monohydrate. CrystEngComm, 2014, 16, 8197.	2.6	17
50	Absorbing a Little Water: The Structural, Thermodynamic, and Kinetic Relationship between Pyrogallol and Its Tetarto-Hydrate. Crystal Growth and Design, 2013, 13, 4071-4083.	3.0	39
51	Chemical transformations of a crystalline coordination polymer: a multi-stage solidâ€“vapour reaction manifold. Chemical Science, 2013, 4, 696-708.	7.4	35
52	Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine. Crystal Growth and Design, 2013, 13, 1602-1617.	3.0	123
53	Zipping and Unzipping of a Paddlewheel Metalâ€“Organic Framework to Enable Twoâ€Step Synthetic and Structural Transformation. Chemistry - A European Journal, 2013, 19, 3552-3557.	3.3	28
54	4th European conference for crystal growth â€“ crystallisation in focus: from fundamentals to application. CrystEngComm, 2013, 15, 2174.	2.6	0

#	Article	IF	Citations
55	Complex Polymorphic System of Gallic Acidâ€"Five Monohydrates, Three Anhydrates, and over 20 Solvates. Crystal Growth and Design, 2013, 13, 19-23.	3.0	97
56	A complementary experimental and computational study of loxapine succinate and its monohydrate. Acta Crystallographica Section C: Crystal Structure Communications, 2013, 69, 1273-1278.	0.4	5
57	Experimental and computational approaches towards solid-form screening of pharmaceuticals. Acta Crystallographica Section A: Foundations and Advances, 2013, 69, s519-s519.	0.3	0
58	2-Methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) propan-2-ol disolvate. Acta Crystallographica Section E: Structure Reports Online, 2013, 69, o752-o753.	0.2	5
59	6-Methyl-1,3,5-triazine-2,4-diamine butane-1,4-diol monosolvate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o3377-o3377.	0.2	2
60	In Situ Monitoring of Stirring Effects on Polymorphic Transformations during Cooling Crystallization of Carbamazepine. Crystal Growth and Design, 2012, 12, 4821-4828.	3.0	40
61	Polymer Templating of Supercooled Indomethacin for Polymorph Selection. ACS Combinatorial Science, 2012, 14, 155-159.	3.8	21
62	Carbamazepine on a carbamazepine monolayer forms unique 1D supramolecular assemblies. Chemical Communications, 2011, 47, 9627.	4.1	3
63	Solid-State Forms of Î²-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?. Crystal Growth and Design, 2011, 11, 210-220.	3.0	55
64	A strategy for producing predicted polymorphs: catemeric carbamazepine form V. Chemical Communications, 2011, 47, 7074.	4.1	176
65	Systematic Data Set for Structureâ^'Property Investigations: Solubility and Solid-State Structure of Alkaline Earth Metal Salts of Benzoates. Crystal Growth and Design, 2011, 11, 1318-1327.	3.0	43
66	Experimental and Predicted Crystal Energy Landscapes of Chlorothiazide. Crystal Growth and Design, 2011, 11, 405-413.	3.0	9
67	Racemic Naproxen: A Multidisciplinary Structural and Thermodynamic Comparison with the Enantiopure Form. Crystal Growth and Design, 2011, 11, 5659-5669.	3.0	53
68	Different structural destinations: comparing reactions of [CuBr2(3-Brpy)2] crystals with HBr and HCl gas. CrystEngComm, 2011, 13, 4400.	2.6	22
69	Data Requirements for the Reliable Use of Atomic Pair Distribution Functions in Amorphous Pharmaceutical Fingerprinting. Pharmaceutical Research, 2011, 28, 1041-1048.	3.5	72
70	Intermolecular interactions, disorder and twinning in ciprofloxacinâ€"2,2-difluoroethanol (2/3) and ciprofloxacinâ€"water (3/14.5). Acta Crystallographica Section C: Crystal Structure Communications, 2011, 67, o120-o124.	0.4	11
71	Precision studies in supramolecular chemistry: a ¹H NMR study of hydroxymethoxyacetophenone/Î²â€cyclodextrin complexes. Magnetic Resonance in Chemistry, 2011, 49, 405-412.	1.9	6
72	A computationally inspired investigation of the solid forms of (R)â€1â€phenylethylammoniumâ€(S)â€2â€phenylbutyrate. Chirality, 2010, 22, 447-455.	2.6	6

#	Article	IF	Citations
73	Mechanistic Insights into a Gasâ€“Solid Reaction in Molecular Crystals: The Role of Hydrogen Bonding. Angewandte Chemie - International Edition, 2010, 49, 8892-8896.	13.8	59
74	Surface-Mediated Two-Dimensional Growth of the Pharmaceutical Carbamazepine. ACS Nano, 2010, 4, 5061-5068.	14.6	15
75	A predicted dimer-based polymorph of 10,11-dihydrocarbamazepine (Form IV). CrystEngComm, 2010, 12, 64-66.	2.6	21
76	Characterisation of amorphous and nanocrystalline molecular materials by total scattering. CrystEngComm, 2010, 12, 1366-1368.	2.6	78
77	Nicotinamideâ€“2,2,2-trifluoroethanol (2/1). Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o727-o728.	0.2	2
78	A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. Journal of Pharmaceutical Sciences, 2009, 98, 4251-4263.	3.3	8
79	Crystal structures with a challenge: high-pressure crystallisation of ciprofloxacin sodium salts and their recovery to ambient pressure. CrystEngComm, 2009, 11, 1396.	2.6	79
80	Hydrogen atom behaviour imaged in a short intramolecular hydrogen bond using the combined approach of X-ray and neutron diffraction. New Journal of Chemistry, 2009, 33, 2486.	2.8	44
81	A chemical preformulation study of a hostâ€“guest complex of cucurbit[7]uril and a multinuclear platinum agent for enhanced anticancer drug delivery. Dalton Transactions, 2009, , 7695.	3.3	61
82	3-Aminocarbonylpyridinium difluoroacetate at 123â€…K. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2896-o2897.	0.2	0
83	Targeted crystallisation of novel carbamazepine solvates based on a retrospective Random Forest classification. CrystEngComm, 2008, 10, 23-25.	2.6	51
84	A Systematic Experimental and Theoretical Study of the Crystalline State of Six Chloronitrobenzenes. Crystal Growth and Design, 2008, 8, 24-36.	3.0	24
85	A catemer-to-dimer structural transformation in cyheptamide. CrystEngComm, 2008, 10, 26-28.	2.6	26
86	Two-dimensional similarity between forms I and II of cytenamide, a carbamazepine analogue. CrystEngComm, 2008, 10, 811.	2.6	21
87	Ureaâ€“N,N-dimethylacetamide (1/1). Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o355-o355.	0.2	2
88	Chlorothiazideâ€“pyridine (1/3). Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1105-o1106.	0.2	4
89	Cytenamide acetic acid solvate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1175-o1176.	0.2	0
90	Cytenamide trifluoroacetic acid solvate. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1215-o1216.	0.2	0

#	Article	IF	Citations
91	Cytenamideâ€“1,4-dioxane (2/1). Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1345-o1346.	0.2	0
92	Cytenamideâ€“butyric acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1295-o1296.	0.2	0
93	Cytenamideâ€“formic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1379-o1380.	0.2	0
94	Search for a Predicted Hydrogen Bonding Motif â^' A Multidisciplinary Investigation into the Polymorphism of 3-Azabicyclo[3.3.1]nonane-2,4-dione. Journal of the American Chemical Society, 2007, 129, 3649-3657.	13.7	61
95	Crystallization and Crystal Energy Landscape of Hydrochlorothiazide. Crystal Growth and Design, 2007, 7, 705-712.	3.0	41
96	Ligand flexibility and framework rearrangement in a new family of porous metalâ€“organic frameworks. Chemical Communications, 2007, , 1532-1534.	4.1	73
97	Reversible Gas Uptake by a Nonporous Crystalline Solid Involving Multiple Changes in Covalent Bonding. Journal of the American Chemical Society, 2007, 129, 15606-15614.	13.7	82
98	Toward the Computational Design of Diastereomeric Resolving Agents:Â An Experimental and Computational Study of 1-Phenylethylammonium-2-phenylacetate Derivatives. Journal of Physical Chemistry B, 2007, 111, 5326-5336.	2.6	47
99	Solving Molecular Crystal Structures from X-ray Powder Diffraction Data: The Challenges Posed by Î³-Carbamazepine and Chlorothiazide N,N,-Dimethylformamide (1/2) Solvate. Journal of Pharmaceutical Sciences, 2007, 96, 1192-1202.	3.3	40
100	Hirshfeld surface analysis of two bendroflumethiazide solvates. Acta Crystallographica Section C: Crystal Structure Communications, 2007, 63, o659-o663.	0.4	14
101	A low-temperature redetermination of cyheptamide. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o205-o206.	0.2	3
102	Powder study of (R)-1-phenylethylammonium (R)-2-phenylbutyrate form 3. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o202-o204.	0.2	3
103	Powder study of (R)-1-phenylethylammonium (R)-2-phenylbutyrate form 2. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o247-o249.	0.2	5
104	10,11-Dihydrocarbamazepine (form III). Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o675-o677.	0.2	11
105	10,11-Dihydrocarbamazepine formic acid solvate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o1469-o1470.	0.2	2
106	ChlorothiazideN,N-dimethylacetamide disolvate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o2422-o2422.	0.2	4
107	Chlorothiazide dimethyl sulfoxide solvate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o2423-o2423.	0.2	4
108	(S)-Trichlormethiazide. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o3685-o3685.	0.2	4

#	Article	IF	Citations
109	Hydroflumethiazide dimethyl sulfoxide disolvate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o3956-o3956.	0.2	2
110	10,11-Dihydrocarbamazepineâ€“formamide solvate (1/1). Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o3888-o3889.	0.2	2
111	10,11-Dihydrocarbamazepineâ€“dimethyl sulfoxide (1/1). Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o3918-o3919.	0.2	3
112	Chlorothiazide formic acid solvate (1/2). Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o4021-o4021.	0.2	4
113	Carbamazepine trifluoroacetic acid solvate. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o4269-o4269.	0.2	6
114	Ureaâ€“N,N-dimethylformamide (3/1). Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o4861-o4861.	0.2	5
115	Control and prediction of packing motifs: a rare occurrence of carbamazepine in a catemeric configuration. CrystEngComm, 2006, 8, 746.	2.6	56
116	Temperature dependence of proton transfer in 4-chlorobenzoic acid. New Journal of Chemistry, 2006, 30, 979.	2.8	31
117	Reversible Extrusion and Uptake of HCl Molecules by Crystalline Solids Involving Coordination Bond Cleavage and Formation. Journal of the American Chemical Society, 2006, 128, 9584-9585.	13.7	113
118	3-Azabicyclo[3.3.1]nonane-2,4-dioneâ€“acetic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o545-o547.	0.2	0
119	Hydrochlorothiazide N,N-dimethylformamide solvate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o1730-o1732.	0.2	5
120	Powder study of chlorothiazideN,N-dimethylformamide solvate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o2216-o2218.	0.2	8
121	Hydrochlorothiazide dimethyl sulfoxide solvate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o2288-o2290.	0.2	3
122	Hydrochlorothiazide N,N-dimethylacetamide disolvate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o2926-o2928.	0.2	4
123	Powder study of 3-azabicyclo[3.3.1]nonane-2,4-dione form 2. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o3046-o3048.	0.2	5
124	Powder study of 3-azabicyclo[3.3.1]nonane-2,4-dione 1-methylnaphthalene hemisolvate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o3752-o3754.	0.2	1
125	HydrochlorothiazideN-methyl-2-pyrrolidone disolvate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o5169-o5171.	0.2	4
126	10,11-Dihydrocarbamazepineâ€“acetic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o5361-o5362.	0.2	2

#	Article	IF	Citations
127	An automated platform for parallel crystallization of small organic molecules. Journal of Applied Crystallography, 2006, 39, 922-924.	4.5	31
128	An Automated Parallel Crystallisation Search for Predicted Crystal Structures and Packing Motifs of Carbamazepine. Journal of Pharmaceutical Sciences, 2006, 95, 1918-1930.	3.3	114
129	Powder diffraction study of 1,2:3,4-dibenzanthracene. Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o1483-o1485.	0.2	2
130	CarbamazepineN,N-dimethylformamide solvate. Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o1509-o1511.	0.2	6
131	Carbamazepine furfural hemisolvate. Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o1777-o1779.	0.2	7
132	3,4-Dichloro-1-nitrobenzeneâ€“aniline (2/1). Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o2318-o2319.	0.2	5
133	Hydrochlorothiazideâ€“aniline (1/1). Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o2520-o2522.	0.2	6
134	Hydrochlorothiazideâ€“1,4-dioxane (1/1). Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o2573-o2575.	0.2	3
135	Powder study of hydrochlorothiazide form II. Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o2798-o2800.	0.2	14
136	Powder study of hydrochlorothiazideâ€“methyl acetate (1/1). Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o2974-o2977.	0.2	3
137	3,4-Dichloro-1-nitrobenzeneâ€“1,4-dioxane (4/1). Acta Crystallographica Section E: Structure Reports Online, 2005, 61, o3666-o3667.	0.2	3
138	Solving molecular crystal structures from laboratory X-ray powder diffraction data withDASH: the state of the art and challenges. Journal of Applied Crystallography, 2005, 38, 249-259.	4.5	82
139	Erosion Characteristics of an Erodible Tablet Incorporated in a Time-Delayed Capsule Device. Drug Development and Industrial Pharmacy, 2005, 31, 79-89.	2.0	26
140	Hydrophobic vs. Hydrophilic:â€‰Ionic Competition in Remacemide Salt Structures. Crystal Growth and Design, 2005, 5, 427-438.	3.0	9
141	Erosion Characteristics of an Erodible Tablet Incorporated in a Time-Delayed Capsule Device. Drug Development and Industrial Pharmacy, 2005, 31, 79-89.	2.0	2
142	Powder study ofN-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]-3-[2-(2-naphthalen-1-ylethoxy)ethylsulfonyl]propylammonium benzoate. Acta Crystallographica Section E: Structure Reports Online, 2004, 60, o1751-o1753.	0.2	5
143	4-Chlorobenzoic acidN,N-dimethylformamide solvate. Acta Crystallographica Section E: Structure Reports Online, 2004, 60, o1950-o1951.	0.2	1
144	The effect of wet granulation on the erosion behaviour of an HPMCâ€“lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 541-549.	4.3	25

#	Article	IF	Citations
145	Indexing Powder Patterns in Physical Form Screening: Instrumentation and Data Quality. Journal of Pharmaceutical Sciences, 2003, 92, 1930-1938.	3.3	66
146	Structure and Dynamics of Maleic Anhydride. Journal of Physical Chemistry A, 2001, 105, 3064-3070.	2.5	15
147	Structural transformations in zopiclone. Chemical Communications, 2001, , 2204-2205.	4.1	26
148	Norfloxacin dihydrate. Acta Crystallographica Section C: Crystal Structure Communications, 2000, 56, 1372-1373.	0.4	35
149	Conformational analysis of Ibuprofen by crystallographic database searching and potential energy calculation. International Journal of Pharmaceutics, 1998, 165, 107-116.	5.2	21
150	Single-crystal neutron refinement of creatine monohydrate at 20 K and 123 K. Journal of the Chemical Society, Faraday Transactions, 1997, 93, 1875-1879.	1.7	12
151	Crystal morphology of ibuprofen predicted from single-crystal pulsed neutron diffraction data. Chemical Communications, 1996, , 855.	4.1	31
152	A single-crystal neutron diffraction study of the temperature dependence of hydrogen-atom disorder in benzoic acid dimers. Journal of the Chemical Society, Faraday Transactions, 1996, 92, 5051.	1.7	131